Fananserin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fananserin
Fananserin.svg
Clinical data
Other namesFananserin
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H24FN3O2S
Molar mass425.519 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Fananserin (RP-62203) is a drug which acts as a potent antagonist at both the 5HT2A receptor,[1] and the Dopamine D4 receptor,[2] but without blocking other dopamine receptors such as D2.[3] It has sedative[4] and antipsychotic effects, and has been researched for the treatment of schizophrenia,[5] although efficacy was less than expected and results were disappointing.[6]

References[edit]

  1. ^ Malleron JL, Comte MT, Gueremy C, Peyronel JF, Truchon A, Blanchard JC, et al. (August 1991). "Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonists". Journal of Medicinal Chemistry. 34 (8): 2477–83. doi:10.1021/jm00112a025. PMID 1908521.
  2. ^ Heuillet E, Petitet F, Mignani S, Malleron JL, Lavayre J, Néliat G, et al. (October 1996). "The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor". European Journal of Pharmacology. 314 (1–2): 229–33. doi:10.1016/s0014-2999(96)00554-7. PMID 8957240.
  3. ^ Doble A, Girdlestone D, Piot O, Allam D, Betschart J, Boireau A, et al. (January 1992). "Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist". British Journal of Pharmacology. 105 (1): 27–36. doi:10.1111/j.1476-5381.1992.tb14206.x. PMID 1596688.
  4. ^ Stutzmann JM, Eon B, Lucas M, Blanchard JC, Laduron PM (April 1992). "RP 62203, a 5-hydroxytryptamine2 antagonist, enhances deep NREM sleep in rats". Sleep. 15 (2): 119–24. doi:10.1093/sleep/15.2.119. PMID 1579785.
  5. ^ Sramek JJ, Kirkesseli S, Paccaly-Moulin A, Davidson J, Jhee SS, Hourani J, et al. "A bridging study of fananserin in schizophrenic patients". Psychopharmacology Bulletin. 34 (4): 811–8. PMID 10513457.
  6. ^ Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Rivière ME, Papillon-Downey C (March 1999). "Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia". The American Journal of Psychiatry. 156 (3): 419–25. doi:10.1176/ajp.156.3.419. PMID 10080558.